Quantum BioPharma Ltd. Opposes Motion to Dismiss in $700 Million Market Manipulation Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has taken a firm stance against a joint motion to dismiss filed by CIBC World Markets and RBC Dominion Securities in the U.S. District Court. This legal action is part of a broader lawsuit where Quantum BioPharma accuses the defendants of engaging in market manipulation through 'spoofing' between January 1, 2020, and August 15, 2024, actions that allegedly violated federal securities laws. The company is seeking damages exceeding $700 million, highlighting the severity of the alleged misconduct.

The lawsuit, pursued on a contingency basis by Christian Attar and Freedman Normand Friedland LLP, claims that the defendants manipulated the market hundreds of times, artificially depressing Quantum’s stock price, which once traded above $460 per share. Quantum BioPharma suspects that additional banks or brokers may be involved in these activities and remains open to exploring potential resolutions. This case underscores the ongoing challenges in ensuring market integrity and the importance of legal mechanisms to address alleged securities violations.

For further details on the lawsuit and Quantum BioPharma's position, interested parties can view the full press release here. The outcome of this lawsuit could have significant implications for market practices and the enforcement of securities laws, making it a closely watched case in the financial and biopharmaceutical sectors.